Table 1 The 2016 WHO classification of acute myeloid leukemia (AML) and related neoplasms

AML with recurrent genetic abnormalities

 AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1

 AML with inv. (16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11

 APL with PML-RARA

 AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A

 AML with t(6;9)(p23;q34.1);DEK-NUP214

 AML with inv. (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM

 AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1

 Provisional entity: AML with BCR-ABL1

 AML with mutated NPM1

 AML with biallelic mutations of CEBPA

 Provisional entity: AML with mutated RUNX1

AML with myelodysplasia-related changes

Therapy-related myeloid neoplasms

AML, NOS

 AML with minimal differentiation

 AML without maturation

 AML with maturation

 Acute myelomonocytic leukemia

 Acute monoblastic/monocytic leukemia

 Pure erythroid leukemia

 Acute megakaryoblastic leukemia

 Acute basophilic leukemia

 Acute panmyelosis with myelofibrosis

Myeloid sarcoma

Myeloid proliferations related to Down syndrome

 Transient abnormal myelopoiesis (TAM)

 Myeloid leukemia associated with Down syndrome